TNGX · Tango Therapeutics, Inc.
$25.60
-0.05 (-0.19%)
At close · Aug 14
Market Cap
$4.32B
Shares
168.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$25.60
Open$25.21
Day$24.75–25.70
52W close$6.36–32.90
Avg vol 30d2.4M
Short int44.6M · 26.5% float · 19.2d
Short vol33%
DataSep 2020–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+39%
above
Price vs 50-day avg
−11%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+101%
trailing
YTD return
+189%
this year
Relative strength
+87%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +78 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
26.46% of float · ▲ +4.4% MoM · 19.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
246 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
+48%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-139.9M
Balance sheet
$112.3M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+39%
Bullish
Price vs 50-day avg
−11%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $29 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +78 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
26.46% of float · ▲ +4.4% MoM · 19.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
246 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $26 · 72%
Range high $33
vs 200-day avg +39%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNGX
this stock
Tango Therapeutics, Inc.
|
$4.32B | +188.9% | +48.3% | — | 26.5% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNGX | -5.4% | -10.4% | +101.1% | -5.8% | +188.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -5.8% | -14.8% | +87.3% | -9.7% | +175.1% |
Key facts
CIK
1819133
CUSIP
87583X109
13F (30d)
245 filings
241 filers
Visit website
Investor relations